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Abstract: Solitary plasmacytoma may be considered as a rare neoplasm of head and neck and 
is a different disease compared to multiple myeloma. The main difference is related to the better 
clinical prognosis of solitary plasmacytoma, which may be clinically silent for several years 
but several local recurrences may be possible once diagnosed and treated. Clinical signs and 
symptoms of solitary plasmacytoma are related to bone pain and possible bone fractures. Partial 
local impairment of local bone function may be present. Bone swelling and local involvement 
of mucosa and local soft tissue may be revealed. Systemic findings related to the production of 
monoclonal protein are usually not present and a monoclonal spike in serum electrophoresis may 
be absent as the monoclonal Bence–Jones protein in the urine. Other systemic dysfunctions as 
systemic bone marrow involvement with related anemia and absent thrombocytopenia. However, 
although very rare, solitary plasmacytoma of the jaw may have several clinical presentations 
and here we review clinical differences reported in the literature.
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Background
Plasmacytoma is a clonal neopastic disorder of bone marrow that originates from 
plasma cells. It is the last maturation stage of B lymphocytes.1,2 A plasmacytoma is 
considered a solitary mass of neoplastic monoclonal plasma cells in either bone or soft 
tissue (ie, extramedullary plasmacytoma). Solitary plasmacytoma may be an isolated 
disease or the first manifestation of a subsequent multiple myeloma.3,4 The isolated 
form of plasmacytoma seems to have a better prognosis,3–5 while in cases of subsequent 
multiple myeloma the prognosis may be different.6 Clonal plasma cells involved in 
plasmacytoma frequently produce a monoclonal immunoglobulin as well as κ or λ 
light chains.7,8 A quantitative assay of plasma monoclonal immunoglubulin may be 
performed during a plasmacytoma and may also reflect tumor growth.9 Commonly 
this described alteration may appear in serum electrophoresis as monoclonal spike in 
the γ area, β area, or rarely in α2 area.10 In cases of light chain production, immuno-
electrophoresis may reveal clonal activity in the patient’s serum and urine.8
Because monoclonal proliferation of plasma cells is localized in the bone marrow 
during solitary plasmacytoma, bone pain, bone destruction, and pathological fractures 
represent the most common clinical sign of the disease.5,11 Moreover, bone damage may 
also be responsible for alteration of blood calcium levels,11 although this alteration is 
more frequent in multiple myeloma than in solitary plasmacytoma.
Clinical complications during plasma cell disorders are also related to immunoglob-
ulin production which is responsible for relative immunodeficiency (specifically, antigen Journal of Blood Medicine 2010:1 34
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immune response seems to be reduced during plasmacytoma) 
and overall kidney damage.1,9,11 Kidney damage are princi-
pally related to light chains with reduced molecular weight 
and which are quickly eliminated as the Bence–Jones protein 
in urine.9,10 Immunoglobulin produced by plasmacytoma 
may be insoluble at cold temperatures, which causes a cryo-
globulinemia,5,12 in particular if a chronic C viral hepatitis is 
associated with the plasmacytoma.5,13,14 In these cases, kidney 
failure may result from reduced immunoglobulin elimination 
in the urine.9 Amyloidosis may be also a consequence of light 
chain production by plasmacytoma.15
A nonsecretory plasmacytoma may rarely be observed,16 
in which κ and λ chains are intracytoplasmic and may be 
detected by immunofluorescence.17
However, plasmacytoma may be divided into different 
clinical forms: soft tissues, extramedullary plasmacytoma, 
solitary plasmacytoma of bone (ie, localized in a single bone), 
or multiple myeloma (ie, systemic disease with multiple bone 
localizations).18 Clinical presentation and signs and symptoms 
are usually different if we consider solitary plasmacytoma and 
systemic multiple myeloma separately (Table 1).
Solitary plasmacytoma of the jaw
Solitary plasmacytoma of bone is a separate entity of plasma 
cell neoplasm and it may located in bone or the extramedul-
lary soft tissue in bone. The localization of solitary plasma-
cytoma of bone in head and neck is very rare and usually the 
sinonasal tract is more involved than other bones.19 Solitary 
bone plasmacytoma is very rarely localized in the jaw. Soli-
tary plasmacytoma of the jaw seems to be related to elderly 
patients and no differences in the frequency were observed 
between males and females. Clinical signs and symptoms 
indicated by patients are localized pain and possible bone 
fracture, but also a bone-impaired function is frequently 
reported.5,11 The presence of progressive bone swelling with 
the involvement of oral mucosa or other soft tissues may be 
also revealed by physical examination.5,11 Asymptomatic 
solitary bone plasmacytoma of the jaw is very rare but such a 
clinical form without pain has been described previously.20
From an epidemiological point of view, plasma cell 
neoplasms affect elderly people aged 50–80 years.5 Clinical 
signs and symptoms may be really poor, therefore it may be 
very difficult to perform an early diagnosis of solitary plas-
macytoma of jaw. Bone pain may be related to other clinical 
oro-maxillofacial diseases, while the involvement of oral 
soft tissues may underestimated.11 Frequently, only after a 
radiologic approach may solitary plasmacytoma of jaw be 
clinically suspected.19,21 In fact, because the main clinical signs 
of solitary plasmacytoma may be summarized in localized 
bone pain and bone alterations, X-ray examination usually 
shows joint alteration, well defined radiographic lesions, and 
bone fractures.5,19,21 Pisano and colleagues reported a localized 
radiolucency on the roots or apices of nearby teeth as radio-
graphic signs of the disease.11,21 Moreover, laboratory signs 
are immunoglobulin production, if the secretory component 
is present (ie, monoclonal gammopathy in serum electropho-
resis, light chain production detectable in serum and/or urine, 
cryoglobulinemia), blood calcium alterations, and kidney 
dysfunction.1,9 Amyloidosis15 and POEMS (polyneuropathy, 
organomegaly, endocrinopathy, multiple myeloma, and skin 
changes) syndrome22 may be observed only as a complication 
of secretory plasmacytoma. In cases of nonsecretory plasma-
cytoma, light chain production is rare, while intracytoplasmic 
monoclonal immunoglobulin production is observed.16,17
Bone marrow aspirate and/or bone marrow biopsy are 
normal in solitary plasmacytoma, and are usually diagnostic 
of multiple myeloma (presence of more than 15% of neoplas-
tic plasma cells).9 Therefore, only a localized bone biopsy 
or surgical approach directed to damaged bone allows the 
identification of a solitary plasmacytoma.
On the other hand, other systemic alterations as hypocal-
cemia, hypecalcemia, anemia, leukopenia, thrombocytopenia, 
and impaired renal function are absent in solitary plasmacy-
toma, but are usually present in multiple myeloma.
Diagnostic criteria for solitary 
bone plasmacytoma
Criteria for identifying solitary bone plasmacytoma vary 
among authors. However, the current criteria to perform 
a diagnosis of solitary plasmacytoma are the following:18 
isolated area of bone destruction due to clonal plasma cells, 
bone marrow plasma cell infiltration not exceeding 5% of 
Table 1 Differences between clinical, laboratory, and radiological 
findings in solitary plasmacytoma of bone and systemic multiple 
myeloma
  SPB MM
Bone pain Present (+) Present (+)
Bone fractures Present (+) Present (++)
Involvement of local soft tissues Present (+) Absent (-)
Radiographic alterations Present (+) Present (++)
Presence of “M” component Possible (±) Present (++)
Presence of light chains in serum 
and/or urine
Possible (±) Present (++)
Kidney damages Absent (-) Present (+)
Altered blood calcium levels Absent (-) Present (+)
Abbreviations: MM, multiple myeloma; SPB, solitary plasmacytoma of bone.Journal of Blood Medicine 2010:1 35
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all nucleated cells, absence of further osteolytic bone lesions 
or other tissue involvement (ie, no evidence of systemic 
plasmacytoma), absence of anemia, hypercalcemia, or renal 
impairment attributable to myeloma, low concentrations of 
serum or urine monoclonal protein (ie, myeloma protein), 
or preserved levels of immunoglobulins.18
Clinical aspects of solitary 
plasmacytoma of jaw
Jaw is a very rare localization of solitary plasmacytoma of 
head and neck,19 and its symptoms may be underestimated 
because they may be considered aspecific. Therefore, clinical 
suspicion of solitary plasmacytoma is difficult and particular 
aspects may differ in laboratory and histological findings. 
Specific symptoms to suspect a diagnosis of solitary plas-
macytoma localized in a unique bone segment are: pain, 
impairment of bone function and movements, presence of 
bone swelling with or without local erosion, involvement of 
local mucosa or tissues, and other systemic symptoms are 
lacking. The clinical presentation of solitary plasmacytoma 
of jaw without pain is very rare, but it has been reported.20
Such abnormalities may be found in laboratory data, 
mainly regarding the possible secretion of monoclonal pro-
tein. Radiologic abnormalities are more common and may be 
found on the roots or apices of nearby teeth as reported by 
Pisano and colleagues.11 Other particular clinical aspects of 
solitary plasmacytoma of jaw were reported in several cases 
in the literature. Lo Munzo and colleagues reported a solitary 
plasmacytoma localized in the jaw of a 53-year-old man. The 
histological examination of the specimen was positive for a 
plasmacytoma with anaplastic appearance and the only clini-
cal sign was localized pain.23 The patient was free of recurrent 
primary disease and was not affected by multiple localiza-
tion.23 In another case reported by our group, a 76-year-old 
woman was affected by solitary plasmacytoma of the left jaw 
and chronic hepatitis C infection. Her clinical presentation was 
with pain and localized swelling in the jaw. Blood examina-
tion showed an increase of gammaglobulin (1.71 g/dL) but 
was negative for serum monoclonal immunoglobulin spike. 
Histological examination of the jaw showed massive diffuse 
stromal infiltration by monoclonal binucleate and trinucleate 
plasmacytes with basophilic cytoplasm, hypodense chromatin, 
and a nucleus with multiple nucleoli. A nonsecretory plas-
macytoma was diagnosed.5 Canger and colleagues reported 
a case of a 76-year-old woman affected by isolated plasma-
cytoma of the mandibular anterior region.20 She underwent 
a surgical interventional for a hip prothesis and an isolated 
plasmacytoma of the jaw was diagnosed two months before 
during presurgical examinations. Local radiotherapy was 
performed and there was no evidence of additional lesions, 
nor bone marrow involvement, during the first radiographic 
follow up. Histological features were numerous plasma cells 
with abundant cytoplasma and eccentrically located nuclei.
Soares Pinto and colleagues reported a case of a 65-year-old 
Black woman with intraoral lesions.24 A physical examination 
disclosed a bluish-red swelling in the left canine area of the 
maxilla. Histological features were sheets of atypical plasma 
cells and monoclonal staining for κ chains was positive. Serum 
electrophoresis revealed an immunoglobulin G monoclonal 
gammopathy. Bone marrow examination displayed more 
than 50% plasmacytosis, but Bence–Jones protein was not 
found in the urine.24 However, abnormalities in light chain 
secretions by monoclonal plasma cells were also reported 
by other authors. Dhaif and colleagues reported a case of a 
solitary plasmocytoma on the left angle of the mandible in a 
46-year-old man.25 Microscopic examination showed extensive 
infiltration of bone by monoclonal plasma cells, with some 
atypical and binucleate forms. The cells demonstrated λ light 
chain restriction. Serum and urine protein electrophoresis 
disclosed a monoclonal peak, identified as immunoglobulin G, 
and Bence – Jones protein was discovered.25 In the same report, 
Dhaif and colleagues described a case of plasmacytoma on 
the right maxilla obliterating the antrum and extending into 
the nose in a 53-year-old man.25 A biopsy was performed 
and the diagnosis of plasmacytoma was confirmed after local 
irradiation with limited surgical approaches. The patient did 
not reveal recurrences in more than 10 years follow-up, which 
confirms that solitary plasmaytoma is associated with a better 
prognosis compared to multiple myeloma.25
Prognosis
The median survival rate of a solitary plasmacytoma is longer 
than in multiple myeloma19,25–27 because of the absence of 
diffused bone marrow alterations, kidney damage, hypercal-
cemia, and related bone fractures.5,26–28 However, full clinical 
remission is unusual.5,26–28 The prognosis of solitary plasma-
cytoma could be worse if recurrence is present as in cases of 
evolution toward systemic disease (multiple myeloma).9
Similarly, the evolution of solitary plasmacytoma of the 
jaw is usually better if there are no recurrences after treatment 
(local surgery, local irradiation, systemic chemotherapy, or a 
combination) or an evolution toward systemic plasmacytoma. 
According to a long-term outcome analysis reported in the 
literature, radiation, chemotherapy, surgery, or a combined 
radiation and surgical approach gave good outcomes with 
a low rate of local recurrence.19,26–28 Nearly 80% of patients 
did not show local recurrence after five years while 20% 
developed multiple myeloma.19Journal of Blood Medicine 2010:1
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Pharmacological toxicity should be considered in treated 
patients, in particular if melphalan is used, because relevant 
side effects such as acute leukemia and other complications 
such as sepsis (a well known complication of chemotherapy-
induced neutropenia) may appear.29–30 Moreover, thrombosis 
has been described as a complication for patients treated with 
thalidomide in particular.31
Solitary plasmacytoma is an isolated disease and the mor-
tality of affected patients may be related to other unrelated 
diseases such as cardiovascular disease.
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